News

Exparel is Pacira’s proprietary drug candidate consisting of bupivacaine encapsulated in DepoFoam, both of which are currently used separately in FDA-approved products. The study results showed less pain

Pirfenidone, a novel antifibrotic and anti-inflammatory drug, inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions including proliferation and differentiation, and plays a key

Decrease in reagent sales led to the decrease in revenue, the company said. Gross profit decreased 51.2% to $2,115,000 from $2,488,000 due to lower sales and the decrease

The company has reported a net loss of $4.37m, or $2.09 loss per diluted share, compared to net loss of $7.34m or $3.90 loss per diluted share, for

Gliclazide is an oral sulfonylurea hypoglycemic agent which stimulates insulin secretion which stimulates beta cells of the islet of Langerhans in the pancreas to release insulin. Gliclazide is

The project starts out with an initial investment of £5m from each partner over a three year period. The collaboration between two UK based pharmaceutical companies, GSK and

The company’s loss from operations was $7.39m, compared to $5.76m for the same period last year. Total operating expenses for the first quarter ended 31 March 2011 were

The Phase I study will investigate the safety, immunological and the biological effect of the drug in patients who are suffering from melanoma. Through intratumoral injection, Ad-RTS-IL-12 employs

SFP is an investigational, continuous iron therapy in late-stage clinical development designed to treat end-stage renal disease (ESRD) patients. Clinical trial data suggests that SFP, delivered via dialysate